To the Editor,

I read the article entitled "Echocardiographic evolution of pulmonary hypertension in female patients with hyperthyroidism" with great interest ([@ref1]). The authors have demonstrated that pulmonary hypertension (PH), with various severities, was present in 73 of the total 142 female patients with hyperthyroidism. To detect PH in the study population, estimated systolic pulmonary arterial pressure (sPAP) was measured by transthoracic echocardiography (TTE). Moreover, patients who had an estimated sPAP ≥35 mm Hg at rest were considered to have PH. I commend the authors for their complementary contribution to the area of PH in patients with hyperthyroidism.

PH is defined as an increase in mean PAP ≥25 mm Hg at rest, as assessed by right heart catheterization (RHC) ([@ref2]). Thus, RHC is considered the gold standard for the diagnosis of PH. However, TTE is recommended for screening for the presence of PH ([@ref2]). Therefore, TTE is frequently used to estimate sPAP, to screen for PH, and to monitor progression over time because it is non-invasive, widely available, and relatively inexpensive.

The estimation of sPAP is based on the peak tricuspid regurgitation velocity (TRV) taking into account right atrial pressure (RAP), as described by the simplified Bernoulli equation ([@ref3]). RAP can be estimated by TTE based on the diameter and respiratory variation in diameter of the inferior vena cava (IVC); an IVC diameter \<2.1 cm that collapses \>50% with a sniff suggests a normal RAP of 3 mm Hg (range, 0--5 mm Hg), whereas an IVC diameter \>2.1 cm that collapses \<50% with a sniff suggests a high RAP of 15 mm Hg (range, 10--20 mm Hg). In scenarios where the IVC diameter and collapse do not fit this paradigm, an intermediate value of 8 mm Hg (range, 5--10 mm Hg) may be used. The EACVI recommends such an approach rather than using a fixed value of 5 or 10 mm Hg for sPAP estimations ([@ref4]).

In the study by Tudoran et al. ([@ref1]), it was not stated whether the diameter and respiratory variation of IVC were evaluated to estimate sPAP. Therefore, I think that it would be more appropriate if these parameters were evaluated as factors in the assessment of sPAP in female patients with hyperthyroidism.

In conclusion, TTE proved to be a reliable method for the assessment of sPAP, being well suited to establish a non-invasive diagnosis of PH ([@ref5]). However, the diameter and respiratory variation of IVC should be taken into account while assessing sPAP rather than using a fixed value of 5 or 10 mm Hg for RAP estimations.
